Exagen Stock Price - XGN

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
CHART Trader
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Exagen Inc XGN NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.32 -1.36% 23.18 24.35 22.27 23.39 23.50 15:34:01
Bid Price Ask Price Spread Spread % News
22.92 23.21 0.29 1.25% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
683 63,877 $ 23.08 $ 1,474,548 108,895 11.54 - 29.858
Last Trade Time Type Quantity Stock Price Currency
15:35:12 5 $ 22.95 USD

Exagen Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 291.16M 12.56M -1.46 -31.38 12.52M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Exagen News

Loading Messages....

Latest XGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical XGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week24.6625.4122.2723.96112,220-1.48-6.0%
1 Month27.0029.85822.2725.0192,003-3.82-14.15%
3 Months14.9529.85813.9621.4186,4318.2355.05%
6 Months16.8029.85811.5419.4384,5206.3837.98%
1 Year16.8029.85811.5419.4384,5206.3837.98%
3 Years16.8029.85811.5419.4384,5206.3837.98%
5 Years16.8029.85811.5419.4384,5206.3837.98%

Exagen Description

Exagen Diagnostics Inc was incorporated under the laws of the state of New Mexico in 2002. The Company is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.